Trial Profile

A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZW 191 (Primary)
Indications Endometrial cancer; Gynaecological cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Zymeworks

22 Apr 2026 Status changed from recruiting to active, no longer recruiting.
22 Apr 2026 Results published in the Media Release
21 Apr 2026 According to a Zymeworks media release, results from the dose-escalation part of the Phase 1 study for ZW191 were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com